Tempus: Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings?
TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.
Read full article »
Tempus is an Illinois-based AI-enabled precision medicine firm that offers solutions such as data collaborations and biological modeling for the life sciences industry.
Read more